On Wednesday, Shares of Energy Transfer Equity LP (NYSE:ETE), lost -4.28% to $ 27.94.
Energy Transfer Equity stated financial results for the quarter ended June 30, 2015.
Distributable Cash Flow, as adjusted, for the three months ended June 30, 2015 was $335 million contrast to $218 million for the three months ended June 30, 2014, an enhance of $117 million. Distributable Cash Flow, as adjusted, per unit was $0.31 for the three months ended June 30, 2015, an enhance of 55% contrast to the three months ended June 30, 2014. ETE’s net income attributable to partners was $298 million for the three months ended June 30, 2015 contrast to $164 million for the three months ended June 30, 2014, an enhance of $134 million.
Energy Transfer Equity, L.P., through its auxiliaries, provides diversified energy-related services in the Unites States. It owns and operates about 7,700 miles of natural gas transportation pipelines and 3 natural gas storage facilities located in the state of Texas; and about 12,800 miles of interstate natural gas pipeline.
Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), declined -4.33% to $7.74, during its last trading session.
ARIAD Pharmaceuticals declared that it will receive $100 million in cash – $50 million upon deal execution late yesterday and an additional $50 million in one year – through a synthetic-royalty financing from PDL BioPharma, Inc. (PDLI) in exchange for paying PDL a mid-single-digit royalty on future sales of Iclusig (ponatinib) until PDL receives a fixed internal rate of return (IRR). ARIAD also has an option, in its discretion, to receive up to an additional $100 million at any time between 6 and 12 months from the date of the agreement, in one or two tranches on comparable terms.
ARIAD intends to use the base funds to conduct a front-line trial of brigatinib, its investigational ALK inhibitor, in patients with non-small cell lung cancer (NSCLC) and to support brigatinib commercial readiness, in addition to to continue its ongoing Iclusig initiatives. ARIAD is on track to complete enrollment in the pivotal ALTA trial of brigatinib in third quarter 2015, to file for approval in the U.S. next year, and subject to regulatory approval, to launch brigatinib by early 2017. Brigatinib has Breakthrough Designation from the U.S. Food and Drug Administration.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
Finally, Dollar General Corp. (NYSE:DG), ended its last trade with 0.84% gain, and closed at $80.68.
Dollar General Corporation, planned to report its financial results for its fiscal 2015-second quarter ended July 31, 2015, on Thursday, August 27, 2015. In connection with the declaration, Todd Vasos, chief executive officer, and John Garratt, interim chief financial officer, will host a conference call on Thursday, August 27, 2015, at 9:00 a.m. CT/10:00 a.m. ET.
Dollar General Corporation, a discount retailer, provides various merchandise products in the southern, southwestern, midwestern, and eastern United States. The company offers consumable products, counting paper and cleaning products comprising paper towels, bath tissues, paper dinnerware, trash and storage bags, and laundry and other home cleaning supplies; packaged food products, such as cereals, canned soups and vegetables, condiments, spices, sugar, and flour; perishables compriseing of milk, eggs, bread, frozen meals, beer, and wine; snacks that comprise candies, cookies, crackers, salty snacks, and carbonated beverages; health and beauty products, such as over-the-counter medicines, in addition to soap, body wash, shampoo, dental hygiene, and foot care products; pet products, which comprise pet supplies and pet food; and tobacco products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
